Stock Track | ImmunityBio Soars 6.39% Post-Market on Strong Revenue Growth and Anktiva Sales Surge

Stock Track

02/26

ImmunityBio, Inc. (NASDAQ:IBRX) shares soared 6.39% in post-market trading on Wednesday, following the release of impressive financial results and operational updates.

The biotechnology company reported a fivefold year-over-year revenue increase, with sales jumping to $38.29 million, surpassing analyst expectations. A key driver was a remarkable 750% increase in unit sales volume for its lead drug, Anktiva, which is approved for the treatment of non-muscle invasive bladder cancer in 33 countries.

Further supporting the positive sentiment, ImmunityBio announced a strategic partnership with Biopharma and Cigalah to commercialize and distribute Anktiva in Saudi Arabia and the broader Middle East and North Africa region. The company is also preparing to submit additional information to the U.S. Food and Drug Administration regarding Anktiva, indicating ongoing regulatory progress.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1187281056"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1187281056\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1187281056?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 09:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187281056","market":"sg","top_or_hot":-1,"title":"Stock Track | ImmunityBio Soars 6.39% Post-Market on Strong Revenue Growth and Anktiva Sales Surge","media":"Stock Track","content":"<p>ImmunityBio, Inc. (NASDAQ:IBRX) shares soared 6.39% in post-market trading on Wednesday, following the release of impressive financial results and operational updates.</p><p>The biotechnology company reported a fivefold year-over-year revenue increase, with sales jumping to $38.29 million, surpassing analyst expectations. A key driver was a remarkable 750% increase in unit sales volume for its lead drug, Anktiva, which is approved for the treatment of non-muscle invasive bladder cancer in 33 countries.</p><p>Further supporting the positive sentiment, ImmunityBio announced a strategic partnership with Biopharma and Cigalah to commercialize and distribute Anktiva in Saudi Arabia and the broader Middle East and North Africa region. The company is also preparing to submit additional information to the U.S. Food and Drug Administration regarding Anktiva, indicating ongoing regulatory progress.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmunityBio Soars 6.39% Post-Market on Strong Revenue Growth and Anktiva Sales Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmunityBio Soars 6.39% Post-Market on Strong Revenue Growth and Anktiva Sales Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-26 09:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmunityBio, Inc. (NASDAQ:IBRX) shares soared 6.39% in post-market trading on Wednesday, following the release of impressive financial results and operational updates.</p><p>The biotechnology company reported a fivefold year-over-year revenue increase, with sales jumping to $38.29 million, surpassing analyst expectations. A key driver was a remarkable 750% increase in unit sales volume for its lead drug, Anktiva, which is approved for the treatment of non-muscle invasive bladder cancer in 33 countries.</p><p>Further supporting the positive sentiment, ImmunityBio announced a strategic partnership with Biopharma and Cigalah to commercialize and distribute Anktiva in Saudi Arabia and the broader Middle East and North Africa region. The company is also preparing to submit additional information to the U.S. Food and Drug Administration regarding Anktiva, indicating ongoing regulatory progress.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1187281056","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187281056","pubTimestamp":1772067768,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ImmunityBio, Inc. (NASDAQ:IBRX) shares soared 6.39% in post-market trading on Wednesday, following the release of impressive financial results and operational updates.The biotechnology company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"个股追踪|ImmunityBio盘后大涨6.39%营收强劲增长Anktiva销量大增","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"ImmunityBio, Inc. (NASDAQ:IBRX) shares soared 6.39% in post-market trading on Wednesday, following the release of impressive financial results and operational updates.The biotechnology company reported a fivefold year-over-year revenue increase, with sales jumping to $38.29 million, surpassing analyst expectations. A key driver was a remarkable 750% increase in unit sales volume for its lead drug, Anktiva, which is approved for the treatment of non-muscle invasive bladder cancer in 33 countries.Further supporting the positive sentiment, ImmunityBio announced a strategic partnership with Biopharma and Cigalah to commercialize and distribute Anktiva in Saudi Arabia and the broader Middle East and North Africa region. The company is also preparing to submit additional information to the U.S. Food and Drug Administration regarding Anktiva, indicating ongoing regulatory progress.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}